XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Cash flows from operating activities:            
Net loss   $ (8,071,596) $ (5,476,807) $ (18,471,409) $ (13,748,774)  
Adjustments to reconcile net loss to net cash from operating activities:            
Depreciation and amortization       572,065 537,211  
Change in fair value of earn-out milestone liability       1,397,291 (3,088,821)  
Impairment of in-process research and development   2,370,257 2,370,257  
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments   400,000  
Recognition of deferred revenue       (375,000) (375,000)  
Stock-based compensation costs       1,448,202 1,762,172  
Shares and warrants issued in exchange for services       44,798 5,350  
Deferred income tax asset       1,819,324  
Amortization of deferred finance charges and debt discount associated with notes payable       439,786 289,182  
Net changes in:            
Accrued interest receivable on investment securities       21,369 41,338  
Advances and deposits on clinical programs and other current assets       (286,991) (951,877)  
Accounts payable- trade and other accrued liabilities       (866,748) 486,857  
Net cash (used in) operating activities:       (11,887,056) (14,642,362)  
Cash flows from investing activities:            
Purchases of investment securities       (9,956,892) (19,338,177)  
Proceeds from sale and maturity of investment securities       17,900,000 23,310,000  
Purchases of property and equipment       (13,918) (336,445)  
Net cash provided by investing activities       7,929,190 3,635,378  
Cash flows from financing activities:            
Proceeds from sale of common stock equity, net of issuance costs $ 1,500,000     20,250,426 6,175,527  
Proceeds from issuance of common stock upon conversion of stock options       371,895  
Payments on notes payable including end-of-term fees       5,200,000  
Proceeds from Payroll Protection Program (PPP) loans       1,324,750  
Repayments on Payroll Protection Program (PPP) loans       (1,324,750)  
Net cash provided by financing activities       15,422,321 6,175,527  
Increase (decrease) in cash and cash equivalents       11,464,455 (4,831,457)  
Cash and cash equivalents at beginning of period       6,875,273 13,353,543 $ 13,353,543
Cash and cash equivalents at end of period $ 18,339,728 $ 18,339,728 $ 8,522,086 18,339,728 8,522,086 $ 6,875,273
Supplemental disclosures of cash flow information:            
Interest paid       (685,913) (760,615)  
Cash paid for amounts included in measurement of lease liabilities:            
Operating cash flows from lease payments       393,947 355,216  
Non-cash financing and investing activities            
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments       400,000  
Right of use assets       1,797,561  
Stock issued in lieu of cash bonus payments       498,632  
Realized and unrealized (gains) losses, net, on investment securities       $ (42,778) $ 4,203